Hollister Closes $20,000,000 Acquisition, Adds $16.4M Revenue & $2.5M EBITDA

At a time when established Cannabis stocks are struggling due to an inability to actually deliver real businesses, Hollister Biosciences (HOLL:CSE) has been quietly building a real business, products, revenue and  customers in 220 of California's 600 dispensaries .... and growing,  including California's #1 hash infused pre-roll "Hashbone".

If that was all Hollister had going, they'd be in great shape with a  super bright future and better than most Cannabis companies (small and  large) who can't even get product out the door.

BUT THERE'S MORE - THE $20,000,000 ACQUISITION THAT COMES WITH $CDN 16.4M REVENUE & $CDN 2.48M EBITDA

Hollister has closed their purchase of Venom Extracts, one of  Arizona's largest producers of Award-Winning Medical Cannabis  Distillate. Just how good is Venom? In 2019, Venom generated $CDN 16.4M  in revenue and $CDN 2.48M EBITDA in 2019 ... and all of that was just  from the state of Arizona.

In this amazing interview, Venom Founder Jake Cohen discusses  Venom's aggressive plans to expand its brand and success into other  states, including California as it benefits from Hollister's  distribution into 220 dispensaries.  Right now, some of you may be  thinking, "yeah but everybody thinks they are going to expand" .... but  Jake's words, as well as those of Alex Somjen (President) and Carl  Saling (CEO) are backed up by action.

Specifically,a significant chunk of Venom's acquisition shares  kicks in if/when revenues hit $CDN 30,000 and $CDN 40,000 .... by  December 31, 2021.  In my experience, companies joining forces don't  include such terms if there isn't a reasonable expectation for hitting  those numbers.  It doesn't guarantee it but you can bet they have good  reason to believe Venom sales will get to one or both of those numbers  in just 21 months from now.

If you're looking for Cannabis companies that are going to survive  and thrive over this next decade, then grab your favourite beverage and  watch this great interview with Carl Saling, Alex Somjen and Jacob  Cohen.